RxDoctor Payments DataLook up a doctor →

Anthony Ricketti, MD

Pulmonary Disease · Trenton, NJNPI 1285680850

Payments from drug & device makers

$225,184in general payments, 2019–2025

Across 889 payments — averaging $253.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$208K
  • AstraZeneca$7K
  • Genentech USA, Inc.$2K
  • CSL Behring$834
  • Sanofi$716
  • Regeneron Healthcare Solutions, Inc.$665
  • plus $6K from 49 others

What the payments were for

  • Consulting fees$1,4731%
  • Speaking & faculty fees$197,62588%
  • Travel & lodging$4,3802%
  • Food & beverage$21,3619%
  • Education$3460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,184 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$148,891
Medicare patients
344
Services billed
4,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate46$604,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter496$443,259
Dupixent SyringeDupilumab92$340,146
NucalaMepolizumab48$172,672
XolairOmalizumab44$172,201
TezspireTezepelumab-Ekko34$142,119
Prolastin CAlpha-1-Proteinase Inhibitor12$133,350
Dupixent PenDupilumab32$132,150
GammakedImmune Globul G/Gly/Iga Avg 4614$115,049
Breo ElliptaFluticasone/Vilanterol152$98,322
Fasenra PenBenralizumab14$79,071
IcatibantIcatibant Acetate11$66,373
Fluticasone-SalmeterolFluticasone Propion/Salmeterol238$53,732
Spiriva RespimatTiotropium Bromide72$48,215
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr87$47,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$208,115$783,591851 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$439$689,656162 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$6,518$205,867166 claims
Grifols USA, LLCProlastin C$346$133,35012 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$74$25,28463 claims
MerckDulera$22$17,63229 claims
Hikma Pharmaceuticals USAEpinephrine$14$4,76020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Trenton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →